JASON ROBERT WESTIN to Biomarkers, Tumor
This is a "connection" page, showing publications JASON ROBERT WESTIN has written about Biomarkers, Tumor.
Connection Strength
0.283
-
Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification. Curr Hematol Malig Rep. 2009 Oct; 4(4):218-24.
Score: 0.093
-
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell. 2019 07 25; 178(3):699-713.e19.
Score: 0.046
-
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2018 10 01; 36(28):2845-2853.
Score: 0.043
-
Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma. Mod Pathol. 2017 12; 30(12):1688-1697.
Score: 0.040
-
What to Do With Success? The Optimist's Creed in Relapsed Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2016 09; 16(9):483-487.
Score: 0.037
-
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021 12; 39(12):1537-1547.
Score: 0.013
-
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma. Blood Cancer J. 2019 05 16; 9(6):48.
Score: 0.011